1. Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors

2. Disclosures

3. Introduction

4. SILEN-C1 trial

5. Virologic responsea

6. Methods

7. Baseline characteristics

8. Virologic response by age and gender

9. Virologic response by baseline ALT and GGT

10. Virologic response by baseline HCV RNA

11. Virologic response by HCV GT-1 subtype

12. Virologic response by IL28B

13. Baseline predictors of SVR

14. Baseline predictors of SVR

15. Discussion

16. Acknowledgements